Overview

Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

Status:
Unknown status
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of TNX-650 for Injection when administered to patients with refractory Hodgkin's lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Tanox